Survey of the use of platelet transfusions in centres participating in MRC leukaemia trials
- 作者Murphy; Murphy; Wheatley; Goldstone
- 卷第102卷
- 期第3期
- 印刷ISSN0007-1048
- 电子ISSN1365-2141
- 文件大小398.86KB
- 发表时间1998
- DOI10.1046/j.1365-2141.1998.0887c.x
- 页码875-876
Bone Cancer || Immunoregulation of Osteoclast Differentiation in Multiple Myeloma Bone DiseaseGrano, Maria · 2010
Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patientsMichael G Alexandrakis; Freda H Passam; Niki Malliaraki; Constantinos Katachanakis; Despina S Kyriakou; Andrew N Margioris · 2002
Management of bone disease in multiple myelomaTerpos, Evangelos; Berenson, James; Raje, Noopur; Roodman, G David · Expert Review of Hematology · 2014
Osteoblast suppression in multiple myeloma bone diseaseAdamik, Juraj; Galson, Deborah L; Roodman, G David · Journal of Bone Oncology · 2018
Bone disease in multiple myeloma: new markers, new treatmentsD. Joshua · 2001
Effects of bortezomib on bone disease in multiple myelomaMatthew T. Drake; S. Vincent Rajkumar · 2009
Pathophysiology and Management of Bone Disease in Multiple MyelomaNiesvizky, Ruben; Warrell, Raymond P. · Cancer Investigation · 1997
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activityClaire M. Shipman; Michael J. Rogers; Jane F. Apperley; R. Graham G. Russell; Peter I. Croucher · 1997
Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myelomaHamdi I. A. Sati; Mike Greaves; Jane F. Apperley; R. Graham G. Russell; Peter I. Croucher · 1999
Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significanceHamdi I. A. Sati; Jane F. Apperley; Mike Greaves; John Lawry; Roger Gooding; R. Graham G. Russell; Peter I. Croucher · 1998